Revenues are coming in
When I summarize the second quarter of 2018, it is gratifying to note that the sale revenue from our TetraGraph system is gaining momentum. We are still in the initial commercialization phase but given the great interest in our products we estimate that we will increase sales significantly in the future. Also gratifying is that we continue associating partners and distributors within new markets. This means that, counting previous distribution and license agreements, we have now started commercialization in 15 markets outside Sweden.
Our strategic goal is to be leaders of the digital transition within anesthesia monitoring that is the current trend within health care. Senzime’s solutions are designated to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Based on signed agreements and planned expansion in additional markets, we estimate that Senzime is well positioned to achieve these above goals. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion.
Senzime offers no sales estimates but, given the above context, it may still be useful to communicate that the company’s working assumption is that our sales will increase from a few million SEK in 2018 to 100 MSEK within a three-year period. The sales will come from a combination of license fees from partner companies as well as from sales of instruments and disposable sensors through our distributors.
In parallel with our own sales, we conduct strategic partnerships. Our collaboration with Philips Healthcare is an example that offers the ability to expand volumes and further increase the intended market. Algorithm and solution upscaling also makes possible expanding the platforms to address further indications.
Overall, it is a very exciting time for Senzime—we have started to build a world-leading patient monitoring company.
Uppsala in August 2018,
Lena Söderström, CEO